TATAA Biocenter, Lexogen Announce Strategic Partnership
News Apr 26, 2016
Lexogen has announced their partnership with TATAA Biocenter. This strategic partnership will expand both Lexogen’s and TATAA’s presence in Europe through TATAA Biocenter’s distribution and support of Lexogen’s NGS products in Sweden, Denmark, Norway, Germany, Austria, France, Luxemburg, Slovakia, and the Czech Republic. TATAA will also incorporate Lexogen’s NGS products in their popular NGS training courses offered throughout the year in various European locations.
Kristina Lind, Coordinator of TATAA Biocenter’s hands-on training program, stated, “We always seek collaboration with the best solution providers for our training courses and Lexogen are top of the class for NGS library preparations.” Mikael Kubista, President of TATAA Biocenter, added, “Our customers request professional tools for the entire NGS workflow from sample preparation and quality control to library preparation, sequencing, and data analysis. With Lexogen´s library construction kits, we can help our customers performing transcription analysis with RNA sequencing at much greater accuracy, reduced cost and higher quality.”
This strategic partnership helps expand the utility of Lexogen’s NGS sample products into key applications, such as transcription analysis, for European end-users. Jekaterina Aleksejeva, Global Marketing Manager at Lexogen, stated, “We are pleased to be partnering with an elite organization like TATAA Biocenter and to have an opportunity to train end users on the value of our differentiated product lines. Enabling researchers to gain valuable information about global gene expression from precious samples is at the core of our organization and working with TATAA will help us to deliver valuable RNA analysis tools to more individuals.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.